Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NCT06686771 · View on ClinicalTrials.gov ↗
Study Summary
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cancer. The usual approach is defined as the care most people get for non-small cell lung cancer.
Conditions Studied
Interventions
- RADIATION SBRT
- OTHER First or second-line standard of care therapy
Study Locations (20)
Illinois
- Alton Memorial Hospital — Alton
- Northwestern University — Chicago
- Decatur Memorial Hospital — Decatur
- Northwestern Medicine Cancer Center Kishwaukee — DeKalb
- Crossroads Cancer Center — Effingham
- Northwestern Medicine Cancer Center Delnor — Geneva
- Northwestern Medicine Glenview Outpatient Center — Glenview
- Northwestern Medicine Grayslake Outpatient Center — Grayslake
- Northwestern Medicine Lake Forest Hospital — Lake Forest
- HSHS Saint Elizabeth's Hospital — O'Fallon
- Northwestern Medicine Oak Brook — Oak Brook
- Northwestern Medicine Orland Park — Orland Park
- Memorial Hospital East — Shiloh
Idaho
- Saint Luke's Cancer Institute - Boise — Boise
- Saint Luke's Cancer Institute - Fruitland — Fruitland
- Saint Luke's Cancer Institute - Meridian — Meridian
- Saint Luke's Cancer Institute - Nampa — Nampa
California
- City of Hope Comprehensive Cancer Center — Duarte
- City of Hope at Irvine Lennar — Irvine
Colorado
- Saint Mary's Hospital and Regional Medical Center — Grand Junction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2025-12-16 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06686771
The ClinicalTrials.gov registry entry for NCT06686771 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Canadian Cancer Trials Group, which has 102 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions — of which SBRT is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06686771 reports 20 study locations spanning 4 distinct geographic areas — top geographies include Illinois, Idaho, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06686771 about?
NCT06686771 is a clinical study titled "Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer". This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cance...
What is the current status of trial NCT06686771?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 2025-12-16. Estimated completion is 2030-12-31.
What conditions does trial NCT06686771 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06686771?
The interventions under investigation include: SBRT (RADIATION), First or second-line standard of care therapy (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06686771?
This trial is sponsored by Canadian Cancer Trials Group, which has 102 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06686771 being conducted?
This trial has 20 study locations across California, Colorado, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.